Avedro, Inc. Announces FDA Submission for Corneal Cross-linking  
3/9/2012 6:44:40 AM

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc. announced today that the Company submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for its VibeX™ (riboflavin ophthalmic solution) /KXL™ System for the treatment of keratoconus and corneal ectasia following refractive surgery.